+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Osteoarthritis Pain Drug Market - Global Forecast 2026-2032- Product Image
Osteoarthritis Pain Drug Market - Global Forecast 2026-2032- Product Image
Sale

Osteoarthritis Pain Drug Market - Global Forecast 2026-2032

  • Report

  • 194 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4995456
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Osteoarthritis Pain Drug Market is projected to reach USD 10.31 Billion in 2026. It is expected to continue growing at a CAGR of 9.62%, reaching USD 17.99 Billion by 2032.

Osteoarthritis pain drug demand is anchored in a large, persistent disease burden. The World Health Organization estimated that 528 million people were living with osteoarthritis in 2019, more than double the 1990 level, with most patients older than 55 and women disproportionately affected. In the United States, the CDC reports that more than 32.5 million adults have osteoarthritis, reinforcing the scale of the treatable pain population.

The market is shaped by the need for safe, long-term pain control across topical nonsteroidal anti-inflammatory drugs (NSAIDs), oral NSAIDs, acetaminophen, duloxetine, intra-articular corticosteroids, and selected adjunctive therapies. Current clinical guidelines prioritize individualized care, risk reduction, and functional improvement, creating opportunities for differentiated osteoarthritis pain drugs that improve tolerability, adherence, and measurable patient outcomes.

Transformative Shifts in the Osteoarthritis Pain Landscape

The osteoarthritis pain treatment landscape is shifting from symptom suppression toward whole-person, risk-adjusted pain management. Clinicians increasingly weigh gastrointestinal, cardiovascular, renal, metabolic, and age-related safety considerations when selecting analgesic therapy, especially for older adults with multiple chronic conditions.

Regulatory and payer scrutiny is also reshaping the competitive environment. Stronger caution around chronic opioid use, expanding use of topical NSAIDs for localized knee and hand pain, and greater attention to real-world evidence are pushing manufacturers to prove durable benefit, safety, and value beyond traditional pain-score endpoints.

Cumulative Impact of Artificial Intelligence on Osteoarthritis Pain Drugs

Artificial intelligence is becoming a practical accelerator across the osteoarthritis pain drug value chain. AI-enabled image analysis, electronic health record mining, natural language processing of clinical notes, and biomarker discovery can help identify pain phenotypes, predict progression, and improve patient selection for clinical trials.

The cumulative impact is especially relevant because osteoarthritis pain is heterogeneous and not always proportional to structural joint damage. Machine learning can support trial enrichment, digital pain monitoring, adherence analysis, pharmacovigilance signal detection, and payer-facing evidence generation, helping companies reduce late-stage uncertainty while improving treatment personalization.

Key Regional Insights Across Global Osteoarthritis Pain Drug Demand

Asia-Pacific is a high-priority region because aging populations in Japan, China, South Korea, Australia, and parts of ASEAN are expanding the pool of patients with knee, hip, and hand osteoarthritis. India and China add scale through large populations, rising diagnosis rates, broader use of branded generics, improving hospital networks, and expanding outpatient pain management access. Japan’s older demographic profile and Australia’s guideline-driven care environment further reinforce demand for safer long-term osteoarthritis pain treatment options.

North America remains a value-defining region due to strong clinical infrastructure, high awareness, and active payer evaluation in the United States and Canada. Europe benefits from mature regulatory systems, national health technology assessment pathways, and guideline-led prescribing, while Latin America is shaped by public-private access expansion in countries such as Brazil and Mexico. The Middle East is influenced by obesity, diabetes, and investment in specialty healthcare infrastructure, and Africa presents access-led opportunities where affordability, primary care capacity, and uneven specialist availability strongly affect osteoarthritis pain drug utilization.

Key Group Insights for Osteoarthritis Pain Drug Strategy

ASEAN demand is supported by population aging, urban lifestyles, rising noncommunicable disease burden, and expanding pharmacy access, although reimbursement depth and regulatory timelines differ by country. The GCC market is influenced by high rates of obesity and metabolic disease, both recognized risk factors for osteoarthritis, alongside strong investment in hospitals, specialty care infrastructure, and digital health systems.

The European Union emphasizes evidence quality, cost-effectiveness, pharmacovigilance, and post-market safety, making it central to value demonstration for osteoarthritis pain drugs. BRICS countries combine large patient pools with pricing pressure, generic competition, public procurement priorities, and local manufacturing objectives. G7 markets lead in guideline adoption, clinical research participation, patient-reported outcome use, and premium access pathways, while NATO-aligned countries increasingly prioritize medicine supply resilience, procurement continuity, and secure pharmaceutical logistics.

Key Country Insights in Osteoarthritis Pain Treatment

The United States is the largest single commercial reference point, supported by CDC-documented osteoarthritis prevalence, advanced pain care networks, broad use of clinical guidelines, and payer scrutiny. Canada follows evidence-based reimbursement and provincial access pathways, while Mexico and Brazil offer growing demand through public-private healthcare channels and expanding chronic disease management. The United Kingdom, Germany, France, Italy, and Spain are shaped by national health systems, health technology assessment, physician guideline adoption, and emphasis on cost-effective prescribing, while Russia remains influenced by local registration requirements, procurement dynamics, and domestic access conditions.

China and India are scale markets with rising diagnosis, large aging populations, high generic competition, and expanding hospital-based pain management. Japan, South Korea, and Australia emphasize aging-related need, quality standards, physician-guided therapy, and careful long-term safety evaluation. Germany and France remain important European evidence markets because of structured reimbursement and clinical assessment expectations, and the United Kingdom continues to influence osteoarthritis pain treatment practice through value-based assessment and national guideline frameworks.

Actionable Recommendations for Osteoarthritis Pain Drug Leaders

Industry leaders should prioritize differentiated safety profiles, especially for patients at elevated gastrointestinal, cardiovascular, renal, metabolic, or polypharmacy risk. Development programs should include older adults, patients with comorbidities, and real-world pain patterns to strengthen clinical relevance and align with how osteoarthritis pain is managed in routine care.

Commercial teams should pair physician education with payer-grade outcomes evidence, including function, rescue medication use, adherence, patient-reported outcomes, and healthcare utilization. Companies should also invest in digital pain tracking, decentralized trial tools, real-world evidence generation, and pharmacovigilance analytics to build credibility across regulators, clinicians, patients, and reimbursement bodies.

Research Methodology for Evidence-Based Market Analysis

This executive summary is based on secondary research from recognized public health agencies, clinical guidelines, regulatory frameworks, peer-reviewed literature, and healthcare policy sources. Key disease-burden references include WHO global osteoarthritis estimates and CDC osteoarthritis data for the United States.

The analysis applies triangulation across epidemiology, treatment guidelines, regulatory signals, access dynamics, regional healthcare infrastructure, aging demographics, and risk-factor evidence. No unsupported market-size, market-share, or growth-rate claims are used; insights are limited to verifiable disease, treatment, policy, access, and adoption indicators relevant to osteoarthritis pain drug strategy.

Conclusion on the Osteoarthritis Pain Drug Opportunity

The osteoarthritis pain drug market is sustained by a large global patient population, aging demographics, and ongoing unmet need for effective, safer long-term pain control. Established therapies remain essential, but treatment selection is becoming more personalized, evidence-driven, and safety-focused as clinicians balance pain relief with comorbidity and tolerability risks.

Future advantage will depend on demonstrating clinically meaningful pain relief, functional improvement, tolerability, adherence, and value in real-world settings. Organizations that combine strong evidence, AI-enabled development, regional access strategy, resilient supply planning, and patient-centered outcomes will be best positioned in the evolving osteoarthritis pain treatment landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Osteoarthritis Pain Drug Market, by Product Type
7.1. Introduction
7.2. Corticosteroids
7.3. Cyclooxygenase 2 Inhibitors
7.4. Nonsteroidal Anti-Inflammatory Drugs
7.5. Symptomatic Slow Acting Drugs
7.6. Viscosupplements
8. Osteoarthritis Pain Drug Market, by Route Of Administration
8.1. Introduction
8.2. Injectable
8.2.1. Intra Articular
8.2.2. Intramuscular
8.3. Oral
8.3.1. Capsules
8.3.2. Liquid
8.3.3. Tablets
8.4. Topical
8.4.1. Cream
8.4.2. Gel
8.4.3. Patch
9. Osteoarthritis Pain Drug Market, by Disease Severity
9.1. Introduction
9.2. Mild
9.3. Moderate
9.4. Severe
10. Osteoarthritis Pain Drug Market, by End User
10.1. Introduction
10.2. Clinics
10.3. Home Healthcare
10.4. Hospitals
11. Osteoarthritis Pain Drug Market, by Application
11.1. Introduction
11.2. Knee Osteoarthritis
11.3. Hip Osteoarthritis
11.4. Hand Osteoarthritis
11.5. Spine Osteoarthritis
12. Osteoarthritis Pain Drug Market, by Distribution Channel
12.1. Introduction
12.2. Offline
12.3. Online
13. Osteoarthritis Pain Drug Market, by Region
13.1. Asia-Pacific
13.2. North America
13.3. Latin America
13.4. Europe
13.5. Middle East
13.6. Africa
14. Osteoarthritis Pain Drug Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Osteoarthritis Pain Drug Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. AbbVie Inc
17.2. Alkem Laboratories Ltd
17.3. Amgen Inc
17.4. Astellas Pharma Inc
17.5. Aurobindo Pharma Ltd
17.6. Bayer AG
17.7. Biocon Ltd
17.8. Bristol Myers Squibb Company
17.9. Cipla Ltd
17.10. Dr Reddy's Laboratories Ltd
17.11. Eli Lilly and Company
17.12. GlaxoSmithKline plc
17.13. Glenmark Pharmaceuticals Ltd
17.14. Ipca Laboratories Ltd
17.15. Johnson & Johnson
17.16. Lupin Ltd
17.17. Mankind Pharma Ltd
17.18. Merck & Co Inc
17.19. Novartis AG
17.20. Pfizer Inc
17.21. Regeneron Pharmaceuticals Inc
17.22. Roche Holding AG
17.23. Sun Pharmaceutical Industries Ltd
17.24. Takeda Pharmaceutical Company Limited
17.25. Teva Pharmaceutical Industries Ltd
17.26. Torrent Pharmaceuticals Ltd
17.27. UCB SA
17.28. Viatris Inc
17.29. Zydus Lifesciences Ltd
List of Figures
FIGURE 1. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 13. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 17. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL CYCLOOXYGENASE 2 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL CYCLOOXYGENASE 2 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL CYCLOOXYGENASE 2 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL SYMPTOMATIC SLOW ACTING DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL SYMPTOMATIC SLOW ACTING DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL SYMPTOMATIC SLOW ACTING DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL VISCOSUPPLEMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL VISCOSUPPLEMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL VISCOSUPPLEMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL INTRA ARTICULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL INTRA ARTICULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL INTRA ARTICULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL LIQUID MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL LIQUID MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL LIQUID MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL TABLETS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL CREAM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL CREAM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL CREAM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL GEL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL GEL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL GEL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL PATCH MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL PATCH MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL PATCH MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL MILD MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL MILD MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL MILD MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL MODERATE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL MODERATE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL MODERATE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL SEVERE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL SEVERE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL SEVERE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL HOME HEALTHCARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL HOME HEALTHCARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL HOME HEALTHCARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL KNEE OSTEOARTHRITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL KNEE OSTEOARTHRITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL KNEE OSTEOARTHRITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL HIP OSTEOARTHRITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL HIP OSTEOARTHRITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL HIP OSTEOARTHRITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL HAND OSTEOARTHRITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL HAND OSTEOARTHRITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL HAND OSTEOARTHRITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL SPINE OSTEOARTHRITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL SPINE OSTEOARTHRITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL SPINE OSTEOARTHRITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL ONLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 97. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 98. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 99. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 100. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 101. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 102. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 103. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 104. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 105. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 106. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 107. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 108. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 109. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 110. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 111. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 112. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 113. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 114. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 115. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 116. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 117. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 118. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 119. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 120. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 121. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 122. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 123. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 124. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 125. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 126. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 127. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 128. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 129. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 130. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 131. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 132. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 133. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 134. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 135. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 136. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 137. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 138. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 139. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 140. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 141. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 142. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 143. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 144. AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 145. AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 146. AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 147. AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 148. AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 149. AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 150. AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 151. AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 152. AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 153. AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 154. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 155. ASEAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 156. ASEAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 157. ASEAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 158. ASEAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 159. ASEAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 160. ASEAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 161. ASEAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 162. ASEAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 163. ASEAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 164. ASEAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 165. GCC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 166. GCC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 167. GCC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 168. GCC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 169. GCC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 170. GCC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 171. GCC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 172. GCC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 173. GCC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 174. GCC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 175. EUROPEAN UNION OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 176. EUROPEAN UNION OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 177. EUROPEAN UNION OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 178. EUROPEAN UNION OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 179. EUROPEAN UNION OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 180. EUROPEAN UNION OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 181. EUROPEAN UNION OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 182. EUROPEAN UNION OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 183. EUROPEAN UNION OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 184. EUROPEAN UNION OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 185. BRICS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 186. BRICS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 187. BRICS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 188. BRICS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 189. BRICS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 190. BRICS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 191. BRICS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 192. BRICS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 193. BRICS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 194. BRICS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 195. G7 OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 196. G7 OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 197. G7 OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 198. G7 OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 199. G7 OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 200. G7 OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 201. G7 OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 202. G7 OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 203. G7 OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 204. G7 OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 205. NATO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 206. NATO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 207. NATO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 208. NATO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 209. NATO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 210. NATO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 211. NATO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 212. NATO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 213. NATO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 214. NATO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 215. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 216. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 217. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 218. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 219. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 220. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 221. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 222. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 223. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 224. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 225. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 226. CANADA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 227. CANADA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 228. CANADA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 229. CANADA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 230. CANADA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 231. CANADA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 232. CANADA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 233. CANADA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 234. CANADA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 235. CANADA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 236. MEXICO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 237. MEXICO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 238. MEXICO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 239. MEXICO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 240. MEXICO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 241. MEXICO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 242. MEXICO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 243. MEXICO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 244. MEXICO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 245. MEXICO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 246. BRAZIL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 247. BRAZIL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 248. BRAZIL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 249. BRAZIL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 250. BRAZIL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 251. BRAZIL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 252. BRAZIL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 253. BRAZIL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 254. BRAZIL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 255. BRAZIL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 256. UNITED KINGDOM OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 257. UNITED KINGDOM OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 258. UNITED KINGDOM OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 259. UNITED KINGDOM OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 260. UNITED KINGDOM OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 261. UNITED KINGDOM OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 262. UNITED KINGDOM OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 263. UNITED KINGDOM OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 264. UNITED KINGDOM OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 265. UNITED KINGDOM OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 266. GERMANY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 267. GERMANY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 268. GERMANY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 269. GERMANY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 270. GERMANY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 271. GERMANY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 272. GERMANY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 273. GERMANY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 274. GERMANY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 275. GERMANY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 276. FRANCE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 277. FRANCE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 278. FRANCE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 279. FRANCE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 280. FRANCE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 281. FRANCE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 282. FRANCE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 283. FRANCE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 284. FRANCE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 285. FRANCE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 286. RUSSIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 287. RUSSIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 288. RUSSIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 289. RUSSIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 290. RUSSIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 291. RUSSIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 292. RUSSIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 293. RUSSIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 294. RUSSIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 295. RUSSIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 296. ITALY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 297. ITALY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 298. ITALY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 299. ITALY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 300. ITALY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 301. ITALY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 302. ITALY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 303. ITALY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 304. ITALY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 305. ITALY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 306. SPAIN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 307. SPAIN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 308. SPAIN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 309. SPAIN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 310. SPAIN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 311. SPAIN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 312. SPAIN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 313. SPAIN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 314. SPAIN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 315. SPAIN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 316. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 317. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 318. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 319. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 320. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 321. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 322. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 323. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 324. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 325. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 326. INDIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 327. INDIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 328. INDIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 329. INDIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 330. INDIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 331. INDIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 332. INDIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 333. INDIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 334. INDIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 335. INDIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 336. JAPAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 337. JAPAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 338. JAPAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 339. JAPAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 340. JAPAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 341. JAPAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 342. JAPAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 343. JAPAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 344. JAPAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 345. JAPAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 346. AUSTRALIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 347. AUSTRALIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 348. AUSTRALIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 349. AUSTRALIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 350. AUSTRALIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 351. AUSTRALIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 352. AUSTRALIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 353. AUSTRALIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 354. AUSTRALIA OSTEOARTHRITIS PAIN DRUG MARKE

Companies Mentioned

  • AbbVie Inc
  • Alkem Laboratories Ltd
  • Amgen Inc
  • Astellas Pharma Inc
  • Aurobindo Pharma Ltd
  • Bayer AG
  • Biocon Ltd
  • Bristol Myers Squibb Company
  • Cipla Ltd
  • Dr Reddy's Laboratories Ltd
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Ltd
  • Ipca Laboratories Ltd
  • Johnson & Johnson
  • Lupin Ltd
  • Mankind Pharma Ltd
  • Merck & Co Inc
  • Novartis AG
  • Pfizer Inc
  • Regeneron Pharmaceuticals Inc
  • Roche Holding AG
  • Sun Pharmaceutical Industries Ltd
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd
  • Torrent Pharmaceuticals Ltd
  • UCB SA
  • Viatris Inc
  • Zydus Lifesciences Ltd

Table Information

Report AttributeDetails
No. of Pages194
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 10.31 Billion
Forecasted Market Value ( USD ) by 2032 $ 17.99 Billion
Compound Annual Growth Rate9.6%
Regions CoveredGlobal
No. of Companies Mentioned29

Related Topics

Related Reports

Neuropathic Pain Drug Market - Global Forecast 2026-2032 - Product Image

Neuropathic Pain Drug Market - Global Forecast 2026-2032

  • Report
  • 187 Pages
  • Global
From
Acute Pain Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type - Product Image

Acute Pain Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

  • Report
  • 117 Pages
  • Global
From
Post Surgical Pain Drug Pipeline Analysis Report 2026 - Product Image

Post Surgical Pain Drug Pipeline Analysis Report 2026

  • Drug Pipelines
  • 150 Pages
  • Global
From
Osteoarthritis Therapeutics Market - Global Forecast 2026-2032 - Product Image

Osteoarthritis Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 191 Pages
  • Global
From
Osteoarthritis Therapeutics - Global Strategic Business Report - Product Image

Osteoarthritis Therapeutics - Global Strategic Business Report

  • Report
  • 266 Pages
  • Global
From

About the Osteoarthritis Pain Drug Market

Analgesics are drugs used to relieve pain. Osteoarthritis pain is a common type of pain that can be treated with analgesics. Osteoarthritis is a degenerative joint disease that causes pain, stiffness, and swelling in the joints. Analgesics used to treat osteoarthritis pain include nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, and opioids. NSAIDs are the most commonly used analgesics for osteoarthritis pain, as they reduce inflammation and pain. Acetaminophen is also used to reduce pain, but it does not reduce inflammation. Opioids are used for severe pain, but they can be addictive and have side effects. Companies in the Osteoarthritis Pain Drug market include Pfizer, Merck, Johnson & Johnson, Novartis, and GlaxoSmithKline. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.